PharVision Advisers’s PACS Group PACS Stock Holding History

PharVision Advisers’s Portfolio PACS Stock Details PACS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,746	Closed	-$259K	–	672
2025 Q4	$259K	Sell	6,746 -7,814	-54%	-$171K	0.13%	371
2025 Q3	$200K	Buy	+14,560	New	+$171K	0.11%	520

Other funds holding PACS

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's PACS Position: Q1 2026 in Review

PharVision Advisers sold out of PACS Group (PACS) in Q1 2026, closing a stake of 6,746 shares — an estimated $259K sold.

PharVision Advisers first reported a position in PACS in Q3 2025 and held it in 2 quarters. The position peaked at $259K in Q4 2025. 216 funds tracked by Wall St. Rank hold PACS as of Q1 2026.

PharVision Advisers reported no remaining PACS Group position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 6,746 PACS Group shares in Q1 2026, an estimated $259K.
PharVision Advisers first reported a position in PACS Group in Q3 2025 and held it in 2 quarters.
PharVision Advisers's PACS Group position peaked at $259K in Q4 2025.
216 funds tracked by Wall St. Rank held PACS Group as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.